Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1466-1472

  Soubirou, J F ^a,b   Rossi, B ^a,b   Couffignal, C ^a,b   Ruppe E ^a,b,c   Chau, F ^b   Massias, L ^a,c   Lepeule, R ^c   Mentre, F ^a,b   Fantin, B ^a,b,c  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Antibiotic pharmacodynamics; Antibiotic resistance; Imipenem

Indexed keywords

IMIPENEM; TEMOCILLIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA-LACTAMASE CTX-M-15; PENICILLIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SINGLE DRUG DOSE; URINARY TRACT INFECTION; ANIMAL; CBA MOUSE; COMPARATIVE STUDY; DISEASE MODEL; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SECRETION (PROCESS); TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; IMIPENEM; MICE, INBRED CBA; MICROBIAL SENSITIVITY TESTS; PENICILLINS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84929715522     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku542     Document Type: Article

References (27)

1. Pitout JDD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-66.
2. Nicolas-Chanoine M-H, Blanco J, Leflon-Guibout V et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61: 273-81.
3. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183 Suppl 1: 1-4.
4. Pitout JDD. Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010; 70: 313-33.
5. Nordmann P, Naas T, Poirel L. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8.
6. Oteo J, Delgado-Iribarren A, Vega D et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 2008; 32: 534-7.
7. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
8. Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother 2009; 63: 243-5.
9. Livermore DM, Hope R, Fagan EJ et al. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from southeast England. J Antimicrob Chemother 2006; 57: 1012-4.
10. Glupczynski Y, Huang T-D, Berhin C et al. In vitro activity of temocillin against prevalent extended-spectrum β-lactamases producing Enterobacteriaceae from Belgian intensive care units. Eur J Clin Microbiol Infect Dis 2007; 26: 777-83.
11. Vanhoof R, Bérin C, Carpentier M et al. Comparative in vitro activity of temocillin and other antimicrobial agents against Enterobacteriaceae isolated from patients admitted to five Belgian hospitals. Acta Clin Belg 2001; 56: 354-9.
12. Andrews JM, Jevons G, Walker R et al. Temocillin susceptibility by BSAC methodology. J Antimicrob Chemother 2007; 60: 185-7.
13. Fuchs PC, Barry AL, Thornsberry C et al. Interpretive criteria for temocillin disk diffusion susceptibility testing. Eur J Clin Microbiol 1985; 4: 30-3.
14. Gupta ND, Smith RE, Balakrishnan I. Clinical efficacy of temocillin. J Antimicrob Chemother 2009; 64: 431-3.
15. Balakrishnan I, Awad-El-Kariem FM, Aali A et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2011; 66: 2628-31.
16. Lepeule R, Ruppé E, Le P et al. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase. Antimicrob Agents Chemother 2012; 56: 1376-81.
17. Pacheco AB, Guth BE, Soares KC et al. Random amplification of polymorphic DNA reveals serotype-specific clonal clusters among enterotoxigenic Escherichia coli strains isolated from humans. J Clin Microbiol 1997; 35: 1521-5.
18. Lavollay M, MamLouk K, Frank T et al. Clonal dissemination of a CTX-M-15 β-lactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui. Antimicrob Agents Chemother 2006; 50: 2433-8.
19. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, 2005.
20. Pearson RD, Steigbigel RT, Davis HT et al. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother 1980; 18: 699-708.
21. De Jongh R, Hens R, Basma V et al. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008; 61: 382-8.
22. Hampel B, Feike M, Koeppe P et al. Pharmacokinetics of temocillin in volunteers. Drugs 1985; 29 Suppl 5: 99-102.
23. Fu KP, Aswapokee P, Ho I et al. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother 1979; 16: 592-7.
24. Leggett JE, Fantin B, Ebert S et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thighinfection models. J Infect Dis 1989; 159: 281-92.
25. Samson A, Lavielle M, Mentré F. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput Stat Data Anal 2006; 51: 1562-74.
26. Frimodt-Møller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002; 9: 546-53.
27. Bush K. Temocillin. In: Finch RG, Greenwood D, Norrby SR et al. eds. Antibiotic and Chemotherapy. London: Churchill Livingstone, 2003; 257-8.